Format

Send to

Choose Destination
Nat Biotechnol. 2018 Nov 19. doi: 10.1038/nbt.4297. [Epub ahead of print]

RNAi modulation of placental sFLT1 for the treatment of preeclampsia.

Author information

1
RNA Therapeutics Institute, University of Massachusetts Medical School, Worcester, Massachusetts, USA.
2
Center for Vascular Biology Research, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.
3
Harvard Medical School, Boston, Massachusetts, USA.
4
Heart Research Institute, Sydney, New South Wales, Australia.
5
School of Medicine, Western Sydney University, Sydney, New South Wales, Australia.
6
Renal Department, Liverpool Hospital, Sydney, New South Wales, Australia.
7
Women's and Babies, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia.
8
Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, California, USA.
9
Moderna Therapeutics, Cambridge, Massachusetts, USA.
10
Program in Molecular Medicine, University of Massachusetts Medical School, Worcester, Massachusetts.

Abstract

Preeclampsia is a placentally induced hypertensive disorder of pregnancy that is associated with substantial morbidity and mortality to mothers and fetuses. Clinical manifestations of preterm preeclampsia result from excess circulating soluble vascular endothelial growth factor receptor FLT1 (sFLT1 or sVEGFR1) of placental origin. Here we identify short interfering RNAs (siRNAs) that selectively silence the three sFLT1 mRNA isoforms primarily responsible for placental overexpression of sFLT1 without reducing levels of full-length FLT1 mRNA. Full chemical stabilization in the context of hydrophobic modifications enabled productive siRNA accumulation in the placenta (up to 7% of injected dose) and reduced circulating sFLT1 in pregnant mice (up to 50%). In a baboon preeclampsia model, a single dose of siRNAs suppressed sFLT1 overexpression and clinical signs of preeclampsia. Our results demonstrate RNAi-based extrahepatic modulation of gene expression with nonformulated siRNAs in nonhuman primates and establish a path toward a new treatment paradigm for patients with preterm preeclampsia.

Supplemental Content

Full text links

Icon for Nature Publishing Group Icon for PubMed Central
Loading ...
Support Center